Humanized BCMA antibody and BCMA-CAR-T cells

Inventors

Wu, Lijun • Golubovskaya, Vita

Assignees

Caribou Biosciences Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12435152-B2

Patent

Publication Date

2025-10-07

Expiration Date


Abstract

The present invention is directed to a humanized BCMA single-chain variable fragment (scFv), comprising VH having the amino acid sequence of SEQ ID NO: 3 and VL having the amino acid sequence of SEQ ID NO: 5. The present invention is also directed to a BCMA chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. This humanized BCMA-CAR-T cells have specific killing activity against BCMA-positive tumor cells.

Core Innovation

The invention describes engineered immune cells expressing an anti-BCMA chimeric antigen receptor with a humanized anti-BCMA single-chain variable fragment. The fragment comprises a heavy chain variable region identified as SEQ ID NO: 3 and a light chain variable region identified as SEQ ID NO: 5. The receptor also comprises a transmembrane domain, a co-stimulatory domain, and a CD3zeta activating domain.

The exemplified receptor uses a CD8 leader and hinge, a CD28 transmembrane and co-stimulatory domain, and CD3zeta. The described CAR-T cells selectively kill BCMA-positive cells, produce IFN-γ, and reduce tumor growth in an RPMI8226 xenograft model without reducing mouse body weight. The partial content does not include the background section, so the problem being solved is not explicitly described in patent.

Claims Coverage

The provided claims identify one independent claim, directed to a method of activating an immune response against BCMA-expressing tumor cells. It contains five main inventive features.

Contacting BCMA-expressing tumor cells

The method comprises contacting the tumor cells with engineered immune cells expressing an anti-BCMA chimeric antigen receptor.

Anti-BCMA single-chain variable fragment

The CAR comprises an anti-BCMA single-chain variable fragment with a heavy chain variable region comprising SEQ ID NO: 3 and a light chain variable region comprising SEQ ID NO: 5.

Selected transmembrane domain

The CAR comprises a transmembrane domain selected from the listed domains, including a T cell receptor α chain, a T cell receptor β chain, CD28, and CD8.

Selected co-stimulatory domain

The CAR comprises a co-stimulatory domain selected from CD28, 4-1BB, GITR, ICOS-1, CD27, OX-40, and DAP10.

CD3zeta activating domain

The CAR comprises a CD3zeta activating domain.

The independent claim combines the specified anti-BCMA variable-region sequences with selected transmembrane and co-stimulatory domains and a CD3zeta activating domain in engineered immune cells used to activate an immune response against BCMA-expressing tumor cells.

Stated Advantages

The described CAR-T cells selectively kill BCMA-positive CHO and multiple-myeloma cells while showing little activity against BCMA-negative controls.

The described CAR-T cells produce IFN-γ.

In an RPMI8226 xenograft model, treatment reduces tumor growth without reducing mouse body weight.

Documented Applications

Activating an immune response against BCMA-expressing tumor cells by contacting them with engineered immune cells expressing the anti-BCMA CAR.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.